Create a Lasting Legacy

Make a lasting impact that will benefit your loved ones and future generations by supporting cancer research. A beneficiary designation is a simple and affordable way to support Research for a Cure. You can easily designate NFCR as a beneficiary in your estate plans or choose one of the options listed below. Consult your financial adviser to maximize tax planning opportunities.

Here are a few ways you can leave your legacy and fund cancer research in the future:

1. Wills
   Gifts left in a will can include cash, securities, or property through a donor’s estate plan.

2. Charitable Gift Annuities
   Gifts providing income for life with guaranteed income to a donor with a portion eligible for a tax deduction.

3. Retirement Account
   Including through a 401K, 403b, traditional IRA or Keogh plan through making NFCR the beneficiary of a portion or the entire plan.

4. Residence or Vacation Home
   Through Retained Life Estate for the life of a donor while receiving a tax deduction for the remainder value.

5. Life Insurance
   By transferring ownership of whole life or universal life policy with cash value to NFCR. Policies transferred have cash value eligible for a tax deduction.

6. Trusts
   Charitable remainder trust or charitable lead trust.

Contact Brian Wachtel, NFCR’s Executive Director, at 301-961-9159 or bwachtel@nfcr.org to start planning a legacy gift to support cancer research today.

Cancer and COVID-19

Cancer screenings are critically important, especially for those with a personal or family history of cancer. Regular cancer screenings are highly recommended, and should not be postponed during COVID-19. Early detection is key to long-term survival.

It is important to take extra precautions in hygiene, social distancing, mask-wearing, and to get sufficient rest and proper nutrition. Continue regular physical check-ups with your medical provider. Many cancers, when detected early, can be successfully treated.

NFCR is helping the cancer community stay informed, prepared, and protected during a challenging time which will be overcome—together.

Please visit our COVID-19 Resource Center at NFCR.org.

The Power of Your Donation

$100
Performs 1 biopsy from a patient for tests and analyses

$250
Supplies 1 case of lab dishes to grow cancer cells to identify tumor markers and test effectiveness of new drugs

$500
Allows 1 antibody test to determine if tumor cells have a drug resistance marker

$1,000
Performs genome-wide analysis in 1 tumor sample to develop targeted and personalized cancer therapies

$2,500
Tests effectiveness of natural product drugs in cancer cells resistant to standard drugs

$5,000
Performs gene identification on biopsy samples from 3 pancreatic cancer patients

New Treatment for Childhood Cancer

Lack of therapies made specifically for young patients forces pediatric oncologists to use adult cancer drugs. In addition to debilitating side effects that can last a lifetime, there are many forms of childhood cancer whose outlook is poor. Unfortunately, financial investment to develop specific pediatric cancer drugs has been dismal.

NFCR’s AIM-HI Translational Research Initiative supports a pipeline to develop treatments for the most common pediatric cancers with the worst outcome. Volasertib is the pipeline’s first drug and will soon reach clinical trials to treat rhabdomyosarcoma, a rare and deadly childhood cancer affecting 450 new patients yearly.

Recently, the FDA granted Rare Pediatric Disease Designation to volasertib which will fast-track the drug approval process. The FDA also awarded volasertib the Orphan Drug Designation (for diseases that affect less than 200,000 individuals) that provides tax credits to reduce clinical trial costs and a waiver of new drug application fees — saving developers of volasertib nearly $2.9 million dollars in 2020.

These benefits will save precious time and money for patients, doctors and drug developers. Your commitment to funding this unmet medical need for better treatments is making a difference in the lives of children.

Thank you for your support
National Foundation for Cancer Research
a 501(c)3 tax-exempt charity (Tax ID: 04-2531031)
5515 Security Lane, Suite 1105, Rockville, MD 20852
NFCR.ORG | 1-800-321-CURE (2873)

Supporter’s Spotlight

“Years ago, I realized that NFCR is an organization whose mission overlapped with mine: Finding the best treatments targeted for each cancer. I hope that one day, cancer can be treated as a chronic disease. Precision medicine makes more sense, and I like the way NFCR scientists are looking for new, non-toxic treatments and cures to help people live longer, healthier lives. I left a gift to NFCR in my will to help carry our vision forward and leave a legacy for future generations.”

—Marilyn W., Eugene, OR

“When I heard how NFCR originated, I said ‘Bravo – for the American people for the grassroots support of NFCR. I’ve lost too many loved ones to cancer, including close relatives and extended family. Although I haven’t had cancer myself, I’ve supported NFCR for 25+ years because research is critically important to all of us.’

—Bill Tost, New York, NY

Cancer claims the lives of 9.5 million people every year. Despite the unprecedented challenges of the global pandemic, our scientists are propelling basic and translational research forward. Your continued support is critically needed to fund high-risk, high-reward research that saves lives. Together, let’s make sure we leave no cancer behind.

—Bill Tost, New York, NY

New Treatment for Childhood Cancer

Lack of therapies made specifically for young patients forces pediatric oncologists to use adult cancer drugs. In addition to debilitating side effects that can last a lifetime, there are many forms of childhood cancer whose outlook is poor. Unfortunately, financial investment to develop specific pediatric cancer drugs has been dismal.

NFCR’s AIM-HI Translational Research Initiative supports a pipeline to develop treatments for the most common pediatric cancers with the worst outcome. Volasertib is the pipeline’s first drug and will soon reach clinical trials to treat rhabdomyosarcoma, a rare and deadly childhood cancer affecting 450 new patients yearly.

Recently, the FDA granted Rare Pediatric Disease Designation to volasertib which will fast-track the drug approval process. The FDA also awarded volasertib the Orphan Drug Designation (for diseases that affect less than 200,000 individuals) that provides tax credits to reduce clinical trial costs and a waiver of new drug application fees — saving developers of volasertib nearly $2.9 million dollars in 2020.

These benefits will save precious time and money for patients, doctors and drug developers. Your commitment to funding this unmet medical need for better treatments is making a difference in the lives of children.

Thank you for your support
National Foundation for Cancer Research
a 501(c)3 tax-exempt charity (Tax ID: 04-2531031)
5515 Security Lane, Suite 1105, Rockville, MD 20852
NFCR.ORG | 1-800-321-CURE (2873)
Botanical Drug Reaches Patients in Clinical Trials

Over two decades of funding from NFCR supporters helped Yung-Chi Cheng, Ph.D. and his team develop YIV-906, a botanical drug with multiple anti-cancer properties that enhance immunotherapy and chemotherapy. NFCR’s AIM-HI Translational Research Initiative support facilitated the translation of YIV-906 to reach the clinical stages.

Now, a global clinical trial is treating liver cancer patients with YIV-906 combined with a frontline drug. Since YIV-906 also protects the gastrointestinal tract from harsh side effects of many therapies, the botanical drug should alleviate adverse effects of the frontline drug that has caused many patients to discontinue its use.

With success in final phase clinical trials, YIV-906 could become the first U.S.-approved botanical cancer drug—a remarkable achievement.

Racial Disparity Research in Lung Cancer

Wei Zhang, Ph.D., found African American lung cancer patients have different mutations in key cancer-related genes than Caucasian patients, contributing to the increased incidence and lower survival rates in African Americans. The Zhang team won a larger national grant to study more patients, which may lead to life-saving treatments to reduce racial disparity in lung cancer survival rates.

Predicting Why Cancer Spreads in Some Patients

Danny Welch, Ph.D., is finding variations in the cell part that produces our body’s energy, possibly explaining why cancer spreads in some patients but not in others. This may partially explain racial disparities in cancer rates and severity. His team’s research suggests a simple blood test could guide doctors to further treat patients whose cancer may spread, and spare patients at low risk from undergoing treatment side effects.

Propelling Development of a New Immunotherapy

With NFCR discovery research funds, Paul Fisher, M.Ph., Ph.D., advanced his powerful immune-stimulating agent as a new treatment to stop the spread of different types of cancer. NFCR’s AIM-HI Translational Research Initiative awarded additional support to bridge the gap between discovery research and expensive clinical drug development required for FDA approval. This year, the AIM-HI funds were matched from another non-profit. Together we are propelling research forward, giving patients new hope for a cure.

Women Researchers Accelerating New Therapy Development

NFCR’s AIM-HI Translational Research Initiative provides the critical funding needed to accelerate promising discoveries to clinical stages and benefit patients. One of its focused areas is to amplify women in oncology who are entrepreneurs and need funds to accelerate their innovative advancements in cancer care to the market.

Before September 24, 2020, the inaugural Women’s Venture Competition was held virtually to connect women researchers from around the globe. An esteemed panel of cancer research leaders selected two semi-finalists from a pool of more than 40 applicants: Stacy Blain, Ph.D. and Manjeh Goldberg, Ph.D. Dr. Blain is developing novel treatments to address drug resistant breast cancer while Dr. Goldberg’s focus is innovative immunotherapy for oral cancer.

NFCR is proud to be a partner organization for this event, supporting and amplifying the contributions of women researchers.

Racial Disparity Research in Lung Cancer
Wei Zhang, Ph.D., found African American lung cancer patients have different mutations in key cancer-related genes than Caucasian patients, contributing to the increased incidence and lower survival rates in African Americans. The Zhang team won a larger national grant to study more patients, which may lead to life-saving treatments to reduce racial disparity in lung cancer survival rates.

Predicting Why Cancer Spreads in Some Patients
Danny Welch, Ph.D., is finding variations in the cell part that produces our body’s energy, possibly explaining why cancer spreads in some patients but not in others. This may partially explain racial disparities in cancer rates and severity. His team’s research suggests a simple blood test could guide doctors to further treat patients whose cancer may spread, and spare patients at low risk from undergoing treatment side effects.

Propelling Development of a New Immunotherapy
With NFCR discovery research funds, Paul Fisher, M.Ph., Ph.D., advanced his powerful immune-stimulating agent as a new treatment to stop the spread of different types of cancer. NFCR’s AIM-HI Translational Research Initiative awarded additional support to bridge the gap between discovery research and expensive clinical drug development required for FDA approval. This year, the AIM-HI funds were matched from another non-profit. Together we are propelling research forward, giving patients new hope for a cure.

Women Researchers Accelerating New Therapy Development
NFCR’s AIM-HI Translational Research Initiative provides the critical funding needed to accelerate promising discoveries to clinical stages and benefit patients. One of its focused areas is to amplify women in oncology who are entrepreneurs and need funds to accelerate their innovative advancements in cancer care to the market.

Before September 24, 2020, the inaugural Women’s Venture Competition was held virtually to connect women researchers from around the globe. An esteemed panel of cancer research leaders selected two semi-finalists from a pool of more than 40 applicants: Stacy Blain, Ph.D. and Manjeh Goldberg, Ph.D. Dr. Blain is developing novel treatments to address drug resistant breast cancer while Dr. Goldberg’s focus is innovative immunotherapy for oral cancer.

NFCR is proud to be a partner organization for this event, supporting and amplifying the contributions of women researchers.